2 July 2024 · 1 min read
PharmaTech is increasingly becoming a category on its own, with PitchBook's Kazi Y. Helal, PhD e...
PharmaTech is increasingly becoming a category on its own, with PitchBook launching a dedicated research report and Q1 2024 seeing $749 million in funding across 39 deals. I think it's worth examining how they define the category, given the interesting mix of CDMO/CMO activities and AI enablement they cluster together.
Filed under AI in Pharma · Tech Bio
PharmaTech is increasingly becoming a category on its own, with PitchBook's Kazi Y. Helal, PhD even launching a dedicated research report. Notably, Q1 2024 saw $749 million in funding across 39 deals.
It is worth having a look at their definition of this category however, as they cluster together an interesting mix of CDMO/CMO activities, around areas like nucleic acid chemistry and Cell&Gene Therapy support, and only partially the latest evolutions in AI enablement of the pharma value chain.
Related insights
11 Dec 2025
My former colleagues at Novartis just signed a $1.7B deal with a seed-stage company.
26 Mar 2026
Earendil Labs just raised $787M for AI-driven biologics. The largest AI biotech round of 2026 so far.
10 Mar 2026
AI drug discovery benchmarks: why pharma needs model evaluation discipline
24 Feb 2026
Europe’s pharma AI risk: value capture matters more than headcount